Japan - Articles and news items

Daiichi Sankyo logo

Daiichi Sankyo and Daiichi Sankyo Espha submit supplemental New Drug Application in Japan for “Cravit® Tablets, Granules” and “Levofloxacin Tablets, Granules DSEP”

Industry news / 1 October 2014 / Daiichi Sankyo

Daiichi Sankyo Company Limited announced that it and its domestic generic subsidiary, Daiichi Sankyo Espha Co., Ltd. have submitted a supplemental New Drug Application (sNDA) in Japan…

Daiichi Sankyo logo

Marketing and manufacturing approval in Japan received for CANAGLU® tablets 100mg

Industry news / 4 July 2014 / Daiichi Sankyo

Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd., announced that Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2 inhibitor, CANAGLU® tablets 100mg (generic name: canagliflozin hydrate, hereafter, CANAGLU®) in Japan, for the treatment of patients with type 2 diabetes mellitus…

Daiichi Sankyo logo

Daiichi Sankyo receives first market approval in Japan for LIXIANA®

Industry news, News / 26 April 2011 / Daiichi Sankyo

LIXIANA® (Edoxaban) is a direct oral factor Xa inhibitor for the prevention of venous thromboembolism…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...